On February 8th Kancera's CEO, Dr. Thomas Olin, presented the company and new data in its ROR inhibitor project on the "6th Swiss-Scandinavian Bio-Business Seminar" in Zurich. In his presentation Dr. Olin described how Kancera, in collaboration with...
Read MoreKancera reports that the company has registered a patent application (EP12153357) for new substances that prevents the ability of the cancer to survive. The new patent is based on Kancera's ROR technology directed against both leukemia and solid tumors....
Read MoreToday Kanceras Chief Scientific Officer, Professor Lars Ährlund-Richter, presents the company and its PFKFB3 inhibitor project at the World Cancer Metabolism Summit in Washington. The meeting brings together world experts in oncology from both the pharmaceutical industry and academia....
Read MoreiNovacia AB, the provider of small molecule drug discovery services, today announced that it has entered into a high-throughput screening collaboration with Agios Pharmaceuticals, Cambridge (MA), USA.
Read MoreKancera report that the Company has registered a patent application for novel compounds targeting the energy metabolism of cancer. The new patent application covers a strategy to facilitate the uptake of substances in cancer cells. These synthetic molecules weaken...
Read MoreIn an ongoing and open collaboration between iNovacia AB, GE Healthcare, Sweden and scientists at the Department of Medical Biochemistry and Biophysics (MBB) at Karolinska Institutet, the surface plasmon resonance and nuclear magnetic resonance techniques have been cross-validated as...
Read MoreKancera co-founder and scientific adviser Professor Håkan Mellstedt has demonstrated a sustained presence of Kancera's ROR1 target over time in patients with non-progressive disease and also a significant increase of this putative tumor target in patients with progressive stages...
Read MoreJanuary 1 - September 30, 2011 All figures relate to the Kancera Group unless otherwise specified. Kancera's acquisition of iNovacia AB was completed on February 17, 2011 and iNovacia AB's operations are therefore included in the financial statements with...
Read MoreAktieägarna i Kancera AB (publ) kallas härmed till extra bolagsstämma torsdagen den 10 november 2011 kl. 16.00 på Kilpatrick Townsend Advokatbyrås kontor, Hovslagargatan 5B, 5 tr i Stockholm.
Read MoreiNovacia, an internationally established contract research company owned by Kancera AB (Nasdaq OMX Stockholm First North, KAN), announces today that highly potent inhibitors of a target protein in the parasite Schistosoma have been developed. This parasite infects annually...
Read More